Development of a chimeric antigen receptor T cell therapy platform at the Mayo Clinic
Biobusiness Grant Recipient: Saad Kenderian, MD
Grant Period: 2017-2018
Award Value: $100,000
Site: Mayo Clinic
In no-cost extension
The goal of this project is to establish the infrastructure for the development of chimeric antigen receptor T (CART) cell therapy at the Mayo Clinic. CART cell therapy has emerged as a potent and potentially curative modality for the treatment of cancer. The technology engineers T cells to make them recognize cancer cells and therefore can be a platform used for the treatment of multiple solid and hematological malignancies. The ultimate goal is to develop a regenerative medicine service line using engineered T cells for the treatment of cancer.